\u2013 In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline\u00ae Depot
(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide
\u2013
CAMBRIDGE, Mass. March 11, 2020 \u2014 Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext:
IPN; ADR: IPSEY) today announced the presentation of the PRESTO study by ENETS, and its
simultaneous publication in the peer-reviewed journal, Advances in Therapy.
1
PRESTO was a multi-national, multi-center, prospective, non-interventional, simulated-use study that
enrolled 90 nurses with \u2265 2 years\u2019 experience injecting with the lanreotide (Somatuline\u00ae Depot)
syringe and\/or the syringe for long-acting release octreotide. The primary objective of the PRESTO
study was to assess nurse preference between the redesigned Somatuline\u00ae Depot syringe and the
syringe for long-acting release octreotide after performing injections into injection pads.
The PRESTO study incorporated an anonymous, web-based questionnaire, where nurses reported
their overall preference. Virtually all participants (97.8%) expressed a preference (85.6% \u201cstrong\u201d,
12.2% \u201cslight\u201d) for the redesigned Somatuline\u00ae Depot syringe versus the octreotide syringe.
Comparative safety and efficacy between Somatuline\u00ae Depot and octreotide were not evaluated in
this study.
“The experiences, attitudes and knowledge of both patients and healthcare practitioners, including
nurses, was essential in the redesign of the syringe,” said Daphne T. Adelman, Clinical Nurse
Specialist from Northwestern University in Chicago, and a lead author on the PRESTO study. “In the
absence of head-to-head trials, these data give healthcare professionals important insights. The
ENETS poster presentation and the Advances in Therapy publication of the PRESTO study provide
further details on the benefits of the redesigned syringe.”
Indications for Somatuline\u00ae Depot include the treatment of adult patients with unresectable, well- or
moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) to improve progression-free survival; treatment of adults with carcinoid
syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy;
and the long-term treatment of patients with acromegaly who have had an inadequate response to
surgery and\/or radiotherapy, or for whom surgery and\/or radiotherapy is not an option. Please see
Important Safety Information below and accompanying full Prescribing Information.
\u201cThe redesigned Somatuline\u00ae Depot syringe was developed based on feedback from physicians,
nurses and patients;
2 and the PRESTO study, for the first time, demonstrates the nurses\u2019 preference
for it versus the octreotide syringe,\u201d said Tamer Garawin, M.D., Vice President, Medical Affairs
Oncology at Ipsen Biopharmaceuticals. \u201cPRESTO is an example of how Ipsen continues our
commitment to partnering with patients and healthcare providers, especially nurses, who play a key
role in the management of GEP-NETs and acromegaly.\u201d
In addition to the PRESTO study, Ipsen had a record 12 abstracts accepted by ENETS.
PRESS RELEASE
*ABOUT PRESTO
PRESTO was a randomized, multinational, multicenter, noninterventional, simulated-use study
involving nurses (n=90) with experience injecting with the Somatuline\u00ae Depot syringe and\/or the
syringe for long-acting release octreotide. The primary objective of this study was to assess
preferences of nurses between injecting with the Somatuline\u00ae Depot syringe and the syringe for longacting release octreotide. Nurses attended a single testing session, during which they injected
injection pads with each type of syringe twice before reporting their preferences. Data were collected
using an anonymous, self-administered, web-based questionnaire. Limitations of this study included
the need for a change in injection pad after 10 injection sessions due to clogging issues which
resulted in two separate cohorts, and that the injections performed were simulated. There were
imbalances noted in sociodemographics and clinical setting of nurses which potentially introduces
biased reporting of preferences. Another limitation was that some nurses were recruited from the
CRO (Contract Research Organization) network organizing the study. This study was not designed to
evaluate the efficacy or safety of Somatuline\u00ae Depot or long-acting release octreotide and no
assessment of efficacy or safety should be interpreted based on this study.
ABOUT NETs
A neuroendocrine tumor (NET) begins in the hormone-producing cells of the body\u2019s neuroendocrine
system, which is made of cells that are a combination of hormone-producing endocrine cells and nerve
cells.3 NETs are a group of uncommon tumors occurring in both men and women aged 50 to 60 years
old although they can affect anyone of any age.3
The three main areas where NETs are found in the body are the gastrointestinal tract, the pancreas
and the lungs.3<\/p>\n\n\n\n
SOMATULINE DEPOT is a registered trademark of IPSEN PHARMA S.A.S.
All other trademarks and registered trademarks are property of their respective owners.
\u00a9 2020 Ipsen Biopharmaceuticals, Inc.
March 2020
SMD-US-003889<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":7,"template":"","categories":[568],"tags":[],"class_list":["post-31856","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-oncology-pressrelease","entry"],"acf":[],"yoast_head":"\n